Determination of causative drugs using ex-vivo expanded skin infiltrating T cells in drug eruptions
| Project/Area Number |
16K10151
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 薬疹 / 原因薬剤 / MDR1 / 重症薬疹 |
|---|
| Outline of Final Research Achievements |
It is not always easy to determine the causative drugs in drug eruption cases. We usually perform DLST, a conventional method to determine the causative drug using peripheral blood mononuclear cells. Suspicious drugs are added to the cells to measure the uptake of 3H-thymidine. However, the detection rate is not satisfactory. Therefor we tried to establish new methods to determine the causative drugs by using ex-vivo expanded skin infiltrating T cells.
We successfully determine the causative drugs in more than half of our cases of drug eruption.
|
| Academic Significance and Societal Importance of the Research Achievements |
再発予防の観点から、薬疹の原因薬剤の同定は非常に重要だが、既存の検査方法ではその陽性率が高くないことから、同定できないケースも多数存在する。既存の方法では同定できなくても、今回我々が開発した、皮膚浸潤T細胞を用いた手法により、同定できたケースも存在し、調べた過半数のケースで同定できたことから、有用な手法と考えられる。
|
Report
(4 results)
Research Products
(5 results)
